MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahj.2024.08.014

Медицинская библиотека · American heart journal · 2024

Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials.

Litwin Sheldon E, Komtebedde Jan, Borlaug Barry A, Kaye David M, Hasenfuβ Gerd, Kawash Rami, Hoendermis Elke, Hummel Scott L, Cikes Maja, Gustafsson Finn, Chung Eugene S, Mohan Rajeev C, Sverdlov Aaron L, Swarup Vijendra, Winkler Sebastian, Hayward Christopher S, Bergmann Martin W, Bugger Heiko, McKenzie Scott, Nair Ajith, Rieth Andreas, Burkhoff Daniel, Cutlip Donald E, Solomon Scott D, van Veldhuisen Dirk J, Leon Martin B, Shah Sanjiv J

СтатьяРандомизированное исследованиеМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

There is a little evidence regarding long-term safety and efficacy for atrial shunt devices in heart failure (HF).

METHODS

The REDUCE LAP-HF I (n = 44) and II (n = 621) trials (RCT-I and -II) were multicenter, randomized, sham-controlled trials of patients with HF and ejection fraction >40%. Outcome data were analyzed from RCT-I, a mechanistic trial with 5-year follow-up, and RCT-II, a pivotal trial identifying a responder group (n = 313) defined by exercise PVR <1.74 WU and no cardiac rhythm management device with 3-year follow-up.

RESULTS

At 5 years in RCT I, there were no differences in cardiovascular (CV) mortality, HF events, embolic stroke, or new-onset atrial fibrillation between groups. After 3 years in RCT II, there was no difference in the primary outcome (hierarchical composite of CV mortality, stroke, HF events, and KCCQ) between shunt and sham in the overall trial. Compared to sham, those with responder characteristics in RCT-II had a better outcome with shunt (win ratio 1.6 [95% CI 1.2-2.2], P = .006; 44% reduction in HF events [shunt 9 vs. control 16 per 100 patient-years], P = .005; and greater improvement in KCCQ overall summary score [+17.9 ± 20.0 vs. +7.6 ± 20.4], P < .001), while nonresponders had significantly more HF events. Shunt treatment at 3 years was associated with a higher rate of ischemic stroke (3.2% vs. 0%, 95% CI 2%-6.1%, P = .032) and lower incidence of worsening kidney dysfunction (10.7% vs. 19.3%, P = .041).

CONCLUSIONS

With up to 5 years of follow up, adverse events were low in patients receiving atrial shunts. In the responder group, atrial shunt treatment was associated with a significantly lower HF event rate and improved KCCQ compared to sham through 3 years of follow-up.

GOV REGISTRATION: NCT02600234, NCT03088033.

Для цитирования: Litwin Sheldon E, Komtebedde Jan, Borlaug Barry A, Kaye David M, Hasenfuβ Gerd, Kawash Rami, Hoendermis Elke, Hummel Scott L, Cikes Maja, Gustafsson Finn, Chung Eugene S, Mohan Rajeev C, Sverdlov Aaron L, Swarup Vijendra, Winkler Sebastian, Hayward Christopher S, Bergmann Martin W, Bugger Heiko, McKenzie Scott, Nair Ajith, Rieth Andreas, Burkhoff Daniel, Cutlip Donald E, Solomon Scott D, van Veldhuisen Dirk J, Leon Martin B, Shah Sanjiv J. Long term safety and outcomes after atrial shunting for heart failure with preserved or mildly reduced ejection fraction: 5-year and 3-year follow-up in the REDUCE LAP-HF I and II trials.. American heart journal. 2024. DOI: 10.1016/j.ahj.2024.08.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.